From: JOAN H JASPER [joanjasper@juno.com]
Sent: Monday, March 19, 2001 9:32 PM
To: fdadockets@oc.fda.gov
Subject: Docket number 00N-0989

This proposal only brings gene therapy and xenotransplantation in
compliance with the same types of information already released to the
public by other government agencies.  Because of grave public health
risks, disclosure should include additional information such as
physicians, medical centers, and so on -- make public all information
except trade secrets and patient identification.

The FDA must assume the sole responsibility for summarizing and
distributing information submitted by the research sponsor, rather than
leave it to the sponsor's discretion.

Because of the public health risks, ethical issues, cost uncertainty, and
the inability to adequately assess other alternatives, all
xenotransplantation clinical trials should stop.

Thank you for your attention.

Yours truly,
(Mrs. ) Joan Jasper
Newark, New York